Programmed death receptor-1 antibodies, tyrosine kinase inhibitors, anti-CD79B antibody–drug conjugates, PIK3 inhibitors, and BCL-2 inhibitors are all used in the treatment of RR DLBCL. Here, BCL2 is linked to diffuse large B-cell lymphoma.